Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia - open-label trial. Arpa J, Sanz-Gallego I, Rodríguez-de-Rivera FJ, Domínguez-Melcón FJ, Prefasi D, Oliva-Navarro J, Moreno-Yangüela M.; Acta Neurol Scand. 2013 May 14. doi: 10.1111/ane.12141.
The triple therapy results seem to indicate some uncertain benefit on the neurological and heart functions in the FRDA.
Subscribe to:
Posts (Atom)
